XNAS · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
TL;DR: MiMedx posted Q1 2026 revenue of $59 million, down 33.1% from $88.2 million in the year-ago quarter, as sweeping Medicare reimbursement changes hit the wound care market hard.
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| BlackRock | 9,313,838 | $64,544,898 | — | 8/13/2024 |
| Vanguard Group | 7,184,262 | $48,637,455 | — | 1/29/2026 |
| State Street | 3,813,796 | $25,819,399 | — | 2/13/2026 |
| Millennium Management | 619,921 | $4,196,865 | — | 2/17/2026 |
| Citadel Advisors | 473,562 | $3,206,014 | — | 2/17/2026 |
| AQR Capital | 407,895 | $2,761,449 | — | 2/17/2026 |
| DE Shaw | 398,908 | $2,700,607 | — | 2/17/2026 |
| JP Morgan Chase | 390,455 | $2,643,380 | — | 2/11/2026 |
| Point72 | 322,290 | $2,181,903 | — | 2/17/2026 |
| Two Sigma | 218,935 | $1,482,190 | — | 2/17/2026 |
| Fidelity (FMR) | 84,245 | $570,340 | — | 2/17/2026 |